In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulus Therapeutics Inc.

www.regulusrx.com

Latest From Regulus Therapeutics Inc.

Rise In Securities Class Action Filings In Life Sciences Sector

Last year proved to be another record period for securities class actions, with a 13% increase in cases filed compared with 2018, and a 24% increase in claims brought against life sciences companies compared with 2018, according to a report by Cornerstone Research: Securities Class Action Filings: 2019 Year In Review.

Business Strategies Commercial

New Mechanisms: Cardior’s Non-Coding RNA Therapeutic For Heart Failure

Germany’s Cardior is conducting clinical studies with an antisense oligonucleotide which inhibits a cellular microRNA believed to be involved in the pathology of heart failure, and is attracting attention from other pharma companies interested in the potential of this new mechanism of action.

Cardiovascular Clinical Trials

Finance Watch: Five IPOs Launch In Two Days; Three Remain In Positive Territory

Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.

Financing Business Strategies

Start-Up Spruce Repurposes Lilly Drug For Genetic Adrenal Condition

Emerging Company Profile: Spruce and Neurocrine are both testing CRF-R1 antagonists for the orphan disease congenital adrenal hyperplasia, with Phase II data coming soon.

StartUps and SMEs Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Renal System
  • Respiratory, Pulmonary
  • Alias(es)
  • Regulus Therapeutics LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Regulus Therapeutics Inc.
  • Senior Management
  • Joseph Hagan, Pres. & CEO
    Cris Calsada, CFO
  • Contact Info
  • Regulus Therapeutics Inc.
    Phone: (888) 734-8587
    10628 Science Center Dr.
    San Diego, CA 92121
    USA
UsernamePublicRestriction

Register